Could base editing therapies reshape precision medicine over the next decade?

Where will base editing make the biggest impact first?

Base editing is most immediately promising for rare, monogenic (single-gene) diseases where a precise DNA change can correct the root cause. The strongest evidence comes from a 2025 case study of a newborn with severe carbamoyl-phosphate synthetase 1 deficiency—a disease with an estimated 50% mortality in early infancy. Within 7 weeks of receiving two infusions of a customized base-editing therapy delivered via lipid nanoparticles, the patient could tolerate more dietary protein and reduced their nitrogen-scavenger medication by half, with no serious adverse events [3]. This is the only published in-human example among the papers reviewed, but it demonstrates that the approach can work in a real, critically ill patient.

Laboratory studies reinforce this potential. In GM1 gangliosidosis—a fatal neurodegenerative lysosomal storage disease with no FDA-approved treatment—researchers used adenine base editing to correct a specific GLB1 gene mutation in patient-derived skin cells. The therapy restored 32.2% of the target allele to the correct sequence and normalized both glycoconjugate storage and lysosomal pathology, with no significant off-target edits detected [9]. Similarly, a 2024 review notes that base and prime editing are being actively developed for inherited retinal dystrophies like choroideremia and Stargardt disease, with clinical trials already underway [8]. These examples share a common thread: the diseases are caused by a single, well-defined genetic typo, making them ideal targets for a tool that swaps one DNA letter for another.

What are the main obstacles to widespread use?

Despite the promise, base editing faces three major barriers: delivery, safety, and cost. Delivery is the most immediate challenge—getting the editing machinery into the right cells in the body without being destroyed or causing immune reactions. The successful 2025 case used lipid nanoparticles (tiny fat bubbles) to carry the base editor, a method that worked for liver-targeted therapy but may not translate to other organs like the brain or heart [3]. A 2024 review of CRISPR applications notes that while viral and non-viral delivery methods are improving, each has limitations in efficiency, tissue specificity, or immunogenicity [4].

Safety concerns center on off-target edits—unintended changes elsewhere in the genome that could cause cancer or other problems. The GM1 gangliosidosis study specifically checked for off-target effects using two computational tools (Cas-OFFinder and CRISTA) and found no significant editing or indels (insertions/deletions) at predicted sites [9]. However, this was in cells in a dish, not in a living patient, and the tools can only predict a subset of potential off-targets. A 2024 review of base editing therapies emphasizes that safety and efficacy in clinical applications remain key areas of ongoing evaluation [1]. Cost is another barrier: the 2025 patient-specific therapy required immediate, customized development after diagnosis, a process that is currently too expensive and slow for common diseases [3]. As one 2025 review puts it, 'production complexities, and high costs continue to hinder widespread adoption' [4].

Can base editing help with common diseases like cancer or sepsis?

Base editing's role in common, complex diseases is less certain and likely further off. For cancer, the technology is being explored to enhance immunotherapies—for example, by editing immune cells to better recognize tumors—but this is still largely preclinical [5][6]. A 2025 review of CRISPR in drug development highlights base editing's potential for 'treating genetic disorders and enhancing cancer immunotherapies,' but provides no human data yet [5].

For conditions like sepsis—a life-threatening immune response to infection—precision medicine is taking a different route. A 2024 review argues that the key advance is not gene editing but patient stratification using omics-based technologies (genomics, proteomics) to identify immune endotypes (subtypes) and then apply targeted immunotherapies [2]. Base editing is not mentioned as a tool for sepsis, because the problem is not a single genetic mutation but a complex, dynamic immune disbalance. Similarly, for autism and epilepsy linked to sodium channel genes, base editing is one of several strategies being tested in preclinical models, alongside antisense oligonucleotides and gene replacement, but no human trials are reported yet [7]. So while base editing may eventually contribute to common diseases, the next decade will likely see its greatest impact in rare, monogenic conditions where the genetic target is clear and the need is urgent.

About These Sources

This answer is built on 9 peer-reviewed studies — published from 2021 to 2026, 8 from 2024 or later, 6 in Q1 journals, collectively cited 521 times — selected as the most relevant from 10 studies that passed quality screening, drawn from 60 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions